Business Wire

Anomali Announces New Platinum Elite Technical Certifications for Global Partner Engineers

Share

Anomali, the leader in modernizing and scaling security operations by delivering breakthrough levels of visibility and intelligence-driven threat detection and response, today announced the availability of its all-new Platinum Elite Technical Certification Program. To further drive the success of Anomali partners and customers, all partner engineers now have access to the same technical curriculum available to Anomali field and customer success engineers, regardless of their current partner level.

Partners that complete certification are eligible for Platinum Elite Status in the Anomali Resilience Partner Program. Since launching its all-new partner program in March 2022, Anomali has continued to invest in the channel, doubling its channel field personnel and hiring a dedicated Director of Channel Enablement.

“To date, the Resilience Partner Program has absolutely energized our partner base, more than tripling our partner engagement in just the first six months,” said Chris Peterson, VP Worldwide Partnerships at Anomali. “By making our Platinum Elite Enablement Program available to all partners – GSI, value-added reseller, or MSP – Anomali is further investing in our partners, providing additional routes to market and enabling new services-driven revenue opportunities.”

The new training is delivered as a hybrid learning model, incorporating both instructor-led and hands-on labs. It comprises three flexible modules, allowing partners to match technical skill development to their business model and scale their Anomali practice. The three available certifications are:

  • Anomali Proof of Value Certified Engineer - Focused on pre-sales technical skill development;
  • Anomali Certified ThreatStream Engineer - Further enabling partner engineers to deliver implementation and integration services for Anomali ThreatStream; and
  • Anomali Platform Certified Engineer - Enabling partner engineers to deliver implementation and integration services for The Anomali Platform.

"The technical certification training from Anomali is phenomenal,” said Paul Lim, Regional Director, ANZ at Netpoleon. “The cloud delivery environment and interaction with Anomali engineers gives us the hands-on experience we can apply immediately into new service offerings for our channel partners and customers."

Platinum Elite is the top tier in the Anomali Resilience Partner Program and provides partners with several enhanced benefits to maximize margins and increase partner routes to market with The Anomali Platform, including:

  • Licensing to The Anomali Platform for the delivery of billable services;
  • Additional margins on the resale of the Anomali solutions;
  • CPE credits against CISSP continuing education requirements for partner engineers; and
  • Enhanced technical knowledge to deliver customer facing POV and implementation engagements.

"Growing a vendor’s business requires technical knowledge transfer to enable a partner to provide implementation and professional services," said Craig Gledhill, CEO, ACA Pacific. “Anomali’s new modular technical enablement program provides this. It also showcases Anomali's continued commitment to the channel, giving our partners’ engineers the skills necessary to deliver great support to their customers and scale their Anomali business.”

The Anomali Platform is a suite of products that work together and easily integrate into existing security stacks across multi-cloud, on-premises, and hybrid deployments. The Integrated product offerings deliver new and uniquely differentiated security visibility use cases to stop attackers and their breaches, including ransomware.

The product suite includes Match, a big data engine that correlates all telemetry with global intelligence to detect and respond at scale; ThreatStream, the leader in threat intelligence management and the largest repository of global intelligence; and Lens, the industry’s only Natural Language Processing (NLP) extension that identifies all threats and IOCs in public and private data to detect the latest threats.

To learn more about today’s announcement and how to become a partner, visit the Anomali Resilience Partner Program.

For more information, visit: www.anomali.com
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog

About Anomali

Anomali is the leader in modernizing and scaling security operations, delivering breakthrough levels of security visibility and intelligence-driven threat detection & response. In a world filled with SIEM, SOAR, XDR, the Anomali Platform amplifies visibility, integrating with existing security controls, and enriching them with actionable context to stop the adversaries. Anomali helps customers and partners transform their SOC platform by elevating security efficacy and reducing their cost with automated processes at the heart of everything. The solution is anchored in big-data management and boasts the world’s largest repository of global intelligence that supports native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses, large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, companies, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali. Learn more at www.anomali.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Karen Buffo
news@anomali.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye